共同药业
(300966)
| 流通市值：12.67亿 | | | 总市值：19.04亿 |
| 流通股本：7666.50万 | | | 总股本：1.15亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 139,216,213.1 | 536,595,592.03 | 365,389,573.73 | 233,822,011.21 |
| 营业收入 | 139,216,213.1 | 536,595,592.03 | 365,389,573.73 | 233,822,011.21 |
| 二、营业总成本 | 144,964,043.16 | 573,756,838.18 | 407,868,913.77 | 250,301,029.55 |
| 营业成本 | 105,466,955.86 | 431,033,318.85 | 313,408,736.73 | 193,177,978.3 |
| 税金及附加 | 295,952 | 1,267,216.98 | 717,440.8 | 578,935.12 |
| 销售费用 | 1,014,561.06 | 6,851,641.4 | 4,678,374.09 | 2,470,416.38 |
| 管理费用 | 13,919,541.36 | 60,971,850.95 | 43,359,989.46 | 26,675,789.13 |
| 研发费用 | 13,895,986.99 | 51,083,365.27 | 32,233,458.68 | 20,278,578.57 |
| 财务费用 | 10,371,045.89 | 22,549,444.73 | 13,470,914.01 | 7,119,332.05 |
| 其中:利息费用 | 10,309,259.83 | 23,518,169.69 | 13,849,116.5 | 8,398,979.56 |
| 其中:利息收入 | 80,886.97 | 1,053,429.94 | 763,775.8 | 576,729.47 |
| 加:公允价值变动收益 | - | 0.18 | 0.05 | 0.05 |
| 加:投资收益 | -270,180.65 | -349,407.59 | 382,374.82 | 253,993.14 |
| 资产处置收益 | -1,572,500.23 | 113,563.03 | -226,823.44 | 27,178.67 |
| 资产减值损失(新) | - | -13,118,322.62 | 6,730,449.33 | 4,155,056.03 |
| 信用减值损失(新) | -1,260,005.94 | -4,429,288.99 | 1,483,124.03 | -1,341,850.4 |
| 其他收益 | 4,526,647.56 | 12,522,760.61 | 6,869,637.77 | 3,225,633.27 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -4,323,869.32 | -42,421,941.53 | -27,240,577.48 | -10,159,007.58 |
| 加:营业外收入 | 69,465.47 | 532,043.14 | 2,833,164.87 | 730,457.78 |
| 减:营业外支出 | 128,800 | 3,645,257 | 1,921,628.83 | 1,914,627.71 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -4,383,203.85 | -45,535,155.39 | -26,329,041.44 | -11,343,177.51 |
| 减:所得税费用 | -3,620,423.52 | -13,879,016.52 | -9,801,079.23 | -4,456,241.22 |
| 六、净利润 | -762,780.33 | -31,656,138.87 | -16,527,962.21 | -6,886,936.29 |
| 持续经营净利润 | -762,780.33 | -31,656,138.87 | -16,527,962.21 | -6,886,936.29 |
| 归属于母公司股东的净利润 | 1,082,077.92 | -27,591,132.24 | -14,162,211.34 | -5,118,586.73 |
| 少数股东损益 | -1,844,858.25 | -4,065,006.63 | -2,365,750.87 | -1,768,349.56 |
| (一)基本每股收益 | 0.01 | -0.24 | -0.12 | -0.04 |
| (二)稀释每股收益 | 0.01 | -0.24 | -0.12 | -0.04 |
| 九、综合收益总额 | -762,780.33 | -31,656,138.87 | -16,527,962.21 | -6,886,936.29 |
| 归属于母公司股东的综合收益总额 | 1,082,077.92 | -27,591,132.24 | -14,162,211.34 | -5,118,586.73 |
| 归属于少数股东的综合收益总额 | -1,844,858.25 | -4,065,006.63 | -2,365,750.87 | -1,768,349.56 |
| 公告日期 | 2025-04-29 | 2025-04-24 | 2024-10-24 | 2024-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |